A new Optum report highlighting upcoming medications in the drug pipeline is meant as a heads-up for payers as they track developments with a couple of therapies for Alzheimer's disease – lecanemab and donanemab. Lecanemab, from Eisai/Biogen, is under review for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease. It's an antibody that binds to